US Market News
1月前
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lokahi Therapeutics to Advance Apitox ProgramMay 5, 2026 2:07 PM
Business Wire Trading Expected to Resume on NYSE American on Tuesday, May 5 Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the “Inscobee Parties”), resolving all outstanding disputes arising from the APUS’ December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company’s previously disclosed $100 million PIPE financing, and the advancement of Lokahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program. APUS’ common stock is expected to resume trading on the NYSE American on Tuesday, May 5, 2026, subject to NYSE approval. Aligned governance. The Inscobee parties have confirmed that the Stockholder Support and Lock-Up Agreement and related voting agreements remain valid and binding, and that prior purported written stockholder consents to remove the Company’s directors are void. Dr. Vin Menon continues to serve as Co-Chief Executive Officer, along with Co-Chief Executive Officer Sungjoon Chae, leading the Newco subsidiary discussed below. The Inscobee parties have granted an irrevocable proxy to vote in favor of the proposals outlined in the Company’s February 27, 2026, Information Statement on Schedule 14C, including the conversion of the Series A Convertible Preferred Stock and outstanding convertible notes and the previously disclosed 1-for-10 reverse stock split. Lokahi to advance the Apitox program. Lokahi, securing the rights relating to the Apitox program, including all relevant intellectual property, regulatory materials, development data, manufacturing information, and all other associated program assets, will deliver $4 million to APUS within five business days following the effective date of the settlement. APUS will also assign to Lokahi the $2.2 million Prevail CRO credit facility to support continued development of the Apitox program. Following payment, APUS will distribute 51% of the common stock of Lokahi as directed by Erik Emerson, the Company’s former Chief Executive Officer, with the Company retaining the remaining 49%. Newco formation. The settlement provides for the formation of a new wholly owned subsidiary of the Company (“Newco”) within seven business days of the effective date. Ten percent of the net proceeds from APUS’ financing arrangement will be allocated to Newco, with the remaining ninety percent allocated to MindWave. Newco is expected to be spun off from the Company within twelve months. About Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. For more information, visit www.apimedsus.com. About MindWave Innovations Inc. MindWave Innovations Inc is a leading provider of institutional Digital Asset Treasury (DAT) solutions, specializing in compliance Bitcoin treasury infrastructure, AI-driven yield capabilities, ClimateTech impact systems, and AdTech engagement platforms. The company’s multi-vertical ecosystem is powered by its native token, $NILA, which enables governance, utility, and value flow across its blockchain-integrated operations. For more information, visit www.mindwavedao.com. About Lokahi Therapeutics Lokahi Therapeutics is focused on advancing innovative therapeutic opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through initiatives like the ai² Futures Lab, Lokahi integrates emerging talent into real-world problem-solving to help shape the future of healthcare. For more information, visit www.lokahithera.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan”, and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds’ results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds’ ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on May 4, 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260505841532/en/ Media Contact:
Dr. Vin Menon
ceo@mindwavedao.com Original: Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lokahi Therapeutics to Advance Apitox Program
US Market News
2月前
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of ChanceryMarch 24, 2026 8:30 AM
Business Wire
MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE American: APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, “Inscobee”), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effect a hostile takeover of the Company’s Board of Directors by written consent.
Inscobee claims to have removed all four sitting directors of APUS and installed three hand-picked replacements without notice to the Company, without authorization from the Company as holder of an irrevocable proxy over Inscobee’s shares, and in direct violation of the Stockholder Support and Lock-Up Agreement that Inscobee itself signed on December 1, 2025.
The Company considers these actions void and of no legal effect.
Inscobee’s actions represent a calculated breach of the contractual framework governing the merger between APUS and MindWave. On December 1, 2025, Inscobee entered into a Stockholder Support and Lock-Up Agreement in which Inscobee, among other things:
Granted APUS an irrevocable proxy over all of their shares, a proxy expressly described as “coupled with an interest” that “may under no circumstances be revoked”; and
Waived their right to exercise consent or voting rights that would impede, disrupt, or adversely affect the consummation of the merger or any contemplated transaction.
Inscobee used 6,416,365 shares--shares subject to the irrevocable proxy--to execute the purported written consent without the Company’s authorization. Without those shares, the consent falls far short of the majority required under Delaware law and is invalid on its face.
MindWave and APUS will file an emergency action in the Delaware Court of Chancery pursuant to 8 Del. C. § 225 seeking a declaration that the purported written consent is void, that the existing Board of Directors remains validly seated, and that the purported new directors hold no valid office. The filing includes a motion for a Temporary Restraining Order to preserve the status quo and prevent the purported directors from taking any corporate action pending judicial resolution.
Engaged legal counsel in Seoul, Korea to investigate and pursue all available remedies against Inscobee under Korean law, including in connection with Inscobee’s conduct toward its own shareholders and its obligations under Korean corporate governance standards.
Notified the Company’s transfer agent that the Board composition is under active dispute and that no changes to stock records or corporate records should be made based on instructions from the purported new directors.
Notified NYSE American of the dispute.
MindWave remains committed to completing the Preferred Stock conversion and all transactions contemplated by the Merger Agreement in an expeditious and lawful manner. The Company will defend the interests of all of its shareholders, including the legacy APUS shareholders whose investments Inscobee have placed at risk through this unlawful action.
The Company intends to pursue every available legal remedy, in both the United States and Korea, to hold Inscobee accountable for the damage their actions have caused and to ensure that binding contractual commitments are honored.
About MindWave Innovations Inc.
MindWave Innovations Inc. is a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS). Through its subsidiary Lokahi Therapeutics, Inc., the Company is focused on the development of innovative therapeutic products.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260324361971/en/
MEDIA CONTACTS
Email: ceo@mindwavedao.com
Original: Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
US Market News
4月前
Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)February 11, 2026 4:51 PM
Business Wire
Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.
The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S.
LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS]). Apimeds and Lokahi Therapeutics are now advancing the program in the U.S. by integrating its historical data with rigorous development standards.
“LT-100, which is currently undergoing manufacturing process enhancements, is taking an important next step toward clinical advancement as we work to align with the FDA on future development strategies,” said Erik Emerson, President of Apimeds and Chief Executive Officer of Lokahi Therapeutics. “LT-100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress.”
“This meeting reflects the extensive analytical and development work undertaken to prepare LT-100 for continued advancement,” said Susan Kramer, DrPH, SVP of Development at Lokahi Therapeutics. “Our team has carefully evaluated the nonclinical, clinical, and manufacturing components of the program to ensure a cohesive and scientifically rigorous development plan. Early and constructive engagement with the FDA is a critical step in responsibly advancing this asset.”
About Apimeds Pharmaceuticals US, Inc
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. For more information visit www.apimedsus.com.
About Lokahi Therapeutics
Lokahi Therapeutics is focused on advancing innovative therapeutic opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through initiatives like the ai² Futures Lab, Lokahi integrates emerging talent into real-world problem-solving to help shape the future of healthcare. For more information visit www.lokahithera.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds’ results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds’ ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on April 15, 2025 (as amended on May 2, 2025).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260211678876/en/
Erik Emerson
CEO
erik@lokhaithera.com
Original: Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
rbl100
2月前
glenn1919
4月前
TommyBoyTrader9460
7月前
81vette
10月前
メールアドレスで登録
